Rare Disease Boom Redefines Pharma Strategy

Big drugmakers step up investment in niche therapies as science and partnerships turn small patient groups into core growth areas

14 Dec 2025

Rare disease therapies are becoming a central pillar of pharmaceutical strategy, as advances in science and a surge in partnerships push what was once a niche market into the industry’s mainstream.

Large drugmakers are increasingly treating treatments for small patient populations as long-term commercial opportunities rather than experimental bets. Recent deals underscore the shift. A licensing agreement between Omeros and Novo Nordisk highlighted how established groups are adding rare disease assets to their pipelines, while Vertex has placed inherited conditions at the heart of its growth plans.

Such moves reflect a broader reassessment of value across the sector. Analysts say companies are drawn by clearer biological targets, regulatory incentives and the prospect of durable revenue from therapies addressing high unmet need. Rare disease programmes, they add, are now often judged alongside mass-market drugs when capital is allocated.

Market forecasts point to sustained expansion. Fortune Business Insights estimates the global rare disease therapeutics market could reach about $469bn by 2032, driven by progress in genetic science and a steady flow of targeted medicines entering development. Other estimates vary, but most predict continued growth as diagnosis rates improve and regulatory pathways mature.

The outlook is not without constraints. High prices for many treatments, particularly one-time or gene-based therapies, remain a concern for payers. Competition is also intensifying as more companies pursue similar disease areas, raising questions about differentiation and long-term returns.

These pressures are prompting changes in how therapies are developed and funded. Analysts point to greater use of partnerships, earlier collaboration between companies and more efficient clinical trial designs. New financing models are also emerging to spread the cost of high-value treatments over time.

Access for patients is expected to improve gradually. Expanded newborn screening and better diagnostic tools could widen the treated population, although progress is likely to vary by region and reimbursement system. Structural barriers in healthcare delivery and funding remain significant.

Despite these challenges, dealmaking and investment show little sign of slowing. Industry participants expect further partnerships, acquisitions and regulatory milestones as companies compete for leadership in specialised but high-impact therapeutic areas.